MA38650A1 - Procede de preparation d'une solution purifiee d'au moins un complexe de radionucleide emetteur alpha - Google Patents
Procede de preparation d'une solution purifiee d'au moins un complexe de radionucleide emetteur alphaInfo
- Publication number
- MA38650A1 MA38650A1 MA38650A MA38650A MA38650A1 MA 38650 A1 MA38650 A1 MA 38650A1 MA 38650 A MA38650 A MA 38650A MA 38650 A MA38650 A MA 38650A MA 38650 A1 MA38650 A1 MA 38650A1
- Authority
- MA
- Morocco
- Prior art keywords
- radionuclide complex
- solution
- preparation
- purified solution
- emitting radionuclide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Extraction Or Liquid Replacement (AREA)
- Saccharide Compounds (AREA)
Abstract
La présente invention concerne un procédé permettant de générer une solution purifiée d'au moins un complexe de radionucléide émetteur alpha. Le procédé comprend la mise en contact d'une solution du complexe de radionucléide émetteur alpha et d'au moins un nucléide fille avec au moins un liant sélectif pour le nucléide fille et, ensuite, la séparation de la solution et du liant sélectif. L'invention concerne également un procédé permettant le retrait d'au moins un radionucléide fille d'une solution comprenant au moins un complexe de radionucléide émetteur alpha. Le procédé comprend la mise en contact de la solution avec au moins un liant pour le nucléide fille.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1310028.4A GB201310028D0 (en) | 2013-06-05 | 2013-06-05 | Pharmaceutical preparation |
| PCT/EP2014/061743 WO2014195423A1 (fr) | 2013-06-05 | 2014-06-05 | Préparation pharmaceutique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38650A1 true MA38650A1 (fr) | 2018-03-30 |
| MA38650B1 MA38650B1 (fr) | 2019-05-31 |
Family
ID=48805787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38650A MA38650B1 (fr) | 2013-06-05 | 2014-06-05 | Procede de preparation d'une solution purifiee d'au moins un complexe de radionucleide emetteur alpha |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US20160114063A1 (fr) |
| EP (1) | EP3003401B1 (fr) |
| JP (1) | JP6580559B2 (fr) |
| KR (1) | KR102321763B1 (fr) |
| CN (1) | CN105592863B (fr) |
| AP (1) | AP2015008894A0 (fr) |
| AU (1) | AU2014276885B2 (fr) |
| BR (1) | BR112015030298A2 (fr) |
| CA (1) | CA2914278C (fr) |
| CL (1) | CL2015003554A1 (fr) |
| CR (1) | CR20150642A (fr) |
| CU (1) | CU24535B1 (fr) |
| DK (1) | DK3003401T3 (fr) |
| DO (1) | DOP2015000294A (fr) |
| EA (1) | EA201501174A1 (fr) |
| ES (1) | ES2782624T3 (fr) |
| GB (1) | GB201310028D0 (fr) |
| HR (1) | HRP20200456T1 (fr) |
| IL (1) | IL242704B (fr) |
| LT (1) | LT3003401T (fr) |
| MA (1) | MA38650B1 (fr) |
| MX (1) | MX366028B (fr) |
| MY (1) | MY180717A (fr) |
| NI (1) | NI201500173A (fr) |
| PE (1) | PE20160215A1 (fr) |
| PH (1) | PH12015502715A1 (fr) |
| PL (1) | PL3003401T3 (fr) |
| PT (1) | PT3003401T (fr) |
| RS (1) | RS60091B1 (fr) |
| SA (1) | SA515370233B1 (fr) |
| SG (1) | SG11201509856RA (fr) |
| SI (1) | SI3003401T1 (fr) |
| TN (1) | TN2015000527A1 (fr) |
| UA (1) | UA120352C2 (fr) |
| WO (1) | WO2014195423A1 (fr) |
| ZA (1) | ZA201600027B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201600158D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Purification method |
| GB201600161D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Isotope purification method |
| AU2022210371A1 (en) | 2021-01-22 | 2023-07-20 | Bayer Aktiengesellschaft | Lrrc15 antibodies and conjugates thereof |
| NO347755B1 (en) * | 2021-10-21 | 2024-03-18 | Blue Wave Therapeutics Gmbh | Peptide-coupled alginate gels comprising radionuclides |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5749042A (en) * | 1997-01-28 | 1998-05-05 | Battelle Memorial Institute | Bismuth generator method |
| GB0308731D0 (en) | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| WO2010126979A1 (fr) * | 2009-04-29 | 2010-11-04 | Bio-Rad Laboratories, Inc. | Purification d'immunoconjugués |
| GB201002508D0 (en) | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201105298D0 (en) * | 2011-03-29 | 2011-05-11 | Algeta Asa | Pharmaceutical preparation |
-
2013
- 2013-06-05 GB GBGB1310028.4A patent/GB201310028D0/en not_active Ceased
-
2014
- 2014-06-05 TN TN2015000527A patent/TN2015000527A1/en unknown
- 2014-06-05 US US14/896,424 patent/US20160114063A1/en not_active Abandoned
- 2014-06-05 AP AP2015008894A patent/AP2015008894A0/xx unknown
- 2014-06-05 ES ES14728571T patent/ES2782624T3/es active Active
- 2014-06-05 BR BR112015030298A patent/BR112015030298A2/pt active Search and Examination
- 2014-06-05 EP EP14728571.2A patent/EP3003401B1/fr active Active
- 2014-06-05 RS RS20200349A patent/RS60091B1/sr unknown
- 2014-06-05 DK DK14728571.2T patent/DK3003401T3/da active
- 2014-06-05 SI SI201431535T patent/SI3003401T1/sl unknown
- 2014-06-05 JP JP2016517608A patent/JP6580559B2/ja not_active Expired - Fee Related
- 2014-06-05 PE PE2015002566A patent/PE20160215A1/es unknown
- 2014-06-05 KR KR1020157036893A patent/KR102321763B1/ko active IP Right Grant
- 2014-06-05 LT LTEP14728571.2T patent/LT3003401T/lt unknown
- 2014-06-05 CU CU2015000174A patent/CU24535B1/es unknown
- 2014-06-05 WO PCT/EP2014/061743 patent/WO2014195423A1/fr active Application Filing
- 2014-06-05 CA CA2914278A patent/CA2914278C/fr active Active
- 2014-06-05 MA MA38650A patent/MA38650B1/fr unknown
- 2014-06-05 PT PT147285712T patent/PT3003401T/pt unknown
- 2014-06-05 SG SG11201509856RA patent/SG11201509856RA/en unknown
- 2014-06-05 EA EA201501174A patent/EA201501174A1/ru unknown
- 2014-06-05 MX MX2015016726A patent/MX366028B/es active IP Right Grant
- 2014-06-05 CN CN201480044621.8A patent/CN105592863B/zh active Active
- 2014-06-05 PL PL14728571T patent/PL3003401T3/pl unknown
- 2014-06-05 UA UAA201512920A patent/UA120352C2/uk unknown
- 2014-06-05 AU AU2014276885A patent/AU2014276885B2/en active Active
- 2014-06-05 MY MYPI2015704399A patent/MY180717A/en unknown
-
2015
- 2015-11-22 IL IL242704A patent/IL242704B/en active IP Right Grant
- 2015-12-03 SA SA515370233A patent/SA515370233B1/ar unknown
- 2015-12-04 PH PH12015502715A patent/PH12015502715A1/en unknown
- 2015-12-04 CL CL2015003554A patent/CL2015003554A1/es unknown
- 2015-12-04 DO DO2015000294A patent/DOP2015000294A/es unknown
- 2015-12-04 NI NI201500173A patent/NI201500173A/es unknown
- 2015-12-04 CR CR20150642A patent/CR20150642A/es unknown
-
2016
- 2016-01-04 ZA ZA2016/00027A patent/ZA201600027B/en unknown
-
2020
- 2020-03-19 HR HRP20200456TT patent/HRP20200456T1/hr unknown
-
2021
- 2021-05-04 US US17/307,857 patent/US20220023449A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201790606A2 (ru) | Катализатор и способ его получения | |
| EA201490583A1 (ru) | Удаление примесных вирусов из препаратов аав | |
| MA38650A1 (fr) | Procede de preparation d'une solution purifiee d'au moins un complexe de radionucleide emetteur alpha | |
| MX2016007297A (es) | Proceso para purificar 2,5-diclorofenol. | |
| MY177751A (en) | Method and device for separating a feed stream using radiation detectors | |
| PE20142094A1 (es) | Metodo para concentrar cloruros metalicos en y separar los mismos de una solucion de acido clorhidrico que contiene cloruro de hierro (iii) | |
| MY180633A (en) | Solid particles, containing lactam, activator, and catalyst, method for producing said solid particles, and use of said solid particles | |
| SA518391338B1 (ar) | عملية لإزالة مركبات الكبريت من تيارات عملية | |
| MX2019012139A (es) | Preparacion de 18f-fluciclovina. | |
| MY170869A (en) | Chuck for chemical vapor deposition systems and related methods therefor | |
| EP3175919A4 (fr) | Procédé de récupération de substance inerte, procédé de fabrication d'acide acrylique en utilisant une substance inerte récupérée par ledit procédé | |
| PH12014501327A1 (en) | Processes for making magnolol analogs | |
| CL2018001012A1 (es) | Métodos y sistemas para retirar compuestos polares de una solución que contiene un metal | |
| IN2014MU03425A (fr) | ||
| FR3024946B1 (fr) | Procede pour determiner le pronostic de survie d'un patient atteint d'un cancer du pancreas | |
| PH12014501220A1 (en) | Removal of components from a starting material | |
| CL2014001748A1 (es) | Procedimiento y dispositivo para extraer un metal a partir de una escoria que contiene el metal, que comprende conectar y desconectar el campo magnetico periodicamente para agitar la escoria periodicamente. | |
| MX2017009727A (es) | Remocion de radionuclidos de mezclas. | |
| MX2017008084A (es) | Detección cuantitativa del ácido siálico utilizando el efecto raman realzado por superficies. | |
| CL2018000197A1 (es) | Aparato de electrodos para la electrodeposición de metales no ferrosos | |
| SA112330683B1 (ar) | طريقة لإزالة أيونات فلز من محلول مائي | |
| BR112017005358A2 (pt) | método para produção de um composto, e, sal de um composto. | |
| MX2015014942A (es) | Proceso de sintesis de ambrox a partir de 13,14,15,16,-tetranor-8a ,12-labdanodiol. | |
| SA518391821B1 (ar) | طريقة لإنتاج حمض الـ (ميث) أكريليك | |
| MA39028A1 (fr) | Système d'administration de médicaments multiparticulaires |